KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Current Leases: 2009-2024

Historic Current Leases for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Dec 2024 value amounting to $41.9 million.

  • Alnylam Pharmaceuticals' Current Leases rose 6.20% to $44.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.8 million, marking a year-over-year increase of 6.20%. This contributed to the annual value of $41.9 million for FY2024, which is 0.91% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Current Leases stood at $41.9 million for FY2024, which was up 0.91% from $41.5 million recorded in FY2023.
  • Alnylam Pharmaceuticals' Current Leases' 5-year high stood at $42.0 million during FY2022, with a 5-year trough of $36.9 million in FY2020.
  • Over the past 3 years, Alnylam Pharmaceuticals' median Current Leases value was $41.9 million (recorded in 2024), while the average stood at $41.8 million.
  • Its Current Leases has fluctuated over the past 5 years, first skyrocketed by 33.17% in 2020, then decreased by 1.09% in 2023.
  • Yearly analysis of 5 years shows Alnylam Pharmaceuticals' Current Leases stood at $36.9 million in 2020, then rose by 9.97% to $40.5 million in 2021, then climbed by 3.50% to $42.0 million in 2022, then declined by 1.09% to $41.5 million in 2023, then rose by 0.91% to $41.9 million in 2024.